Skip to main content
OpenTrials

Clinical trial condition

Respiratory Syncytial Virus Infections

Explore clinical trials studying Respiratory Syncytial Virus Infections. Study availability and eligibility vary by location and protocol.

248 public trials 23 recruiting studies
Refine in advanced search Browse all conditions

Respiratory Syncytial Virus Infections trial results

Completed

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

NCT04288921

Conditions
Infections, Influenza, Human, Mononegavirales Infections, +8 more
Locations
  • MedHelp Urgent Care Birmingham, Alabama, United States
  • Access Medical Center Encinitas, California, United States
  • Madera Family Medical Group Madera, California, United States
  • ImmunoE Health and Research Centennial, Colorado, United States
View all 20 locations
View Trial Details
Completed

A Study on the Immune Response and Safety of an RSV Vaccine When Given to Adults 18 Years of Age and Above Who Received Lung or Kidney Transplant and Are at an Increased Risk of Respiratory Syncytial Virus Lower Respiratory Tract Disease and Compared to Healthy Adults 50 Years of Age and Above

NCT05921903

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Chicago, Illinois, United States
  • GSK Investigational Site Lexington, Kentucky, United States
  • GSK Investigational Site Minneapolis, Minnesota, United States
View all 46 locations
View Trial Details
Completed

A Study on the Immune Response, Safety and the Occurrence of Respiratory Syncytial Virus (RSV)-Associated Respiratory Tract Illness After Administration of RSV OA Vaccine in Adults 60 Years and Older

NCT06551181

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Shanghai, Putuo, China
  • GSK Investigational Site Shanghai, Putuo, China
  • GSK Investigational Site Shanghai, Shanghai Municipality, China
  • GSK Investigational Site Shanghai, China
View all 40 locations
View Trial Details
Completed

The Immunology and Safety of Maternal RSV Vaccination (ABRYSVO), Infant Nirsevimab (BEYFORTUS) Immunization, or Both Products

NCT06551506

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +5 more
Locations
  • Emory University School of Medicine Atlanta, Georgia, United States
  • University of Maryland, School of Medicine, Center for Vaccine Development and Global Health Baltimore, Maryland, United States
  • New York University School of Medicine - Langone Medical Center - Vaccine Center New York, United States
  • University of Rochester Medical Center - Vaccine Research Unit Rochester, New York, United States
View Trial Details
Completed

Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

NCT04938830

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +5 more
Locations
  • Miller Children's & Women's Hospital Long Beach ( Site 0001) Long Beach, California, United States
  • Children's Hospital of Orange County ( Site 0047) Orange, California, United States
  • Children's Hospital Colorado ( Site 0011) Aurora, Colorado, United States
  • Children's National Medical Center ( Site 0020) Washington D.C., District of Columbia, United States
View all 146 locations
View Trial Details
Completed

Study to Evaluate the Safety and Immunogenicity of Investigational Vaccines Using the RSV (Respiratory Syncytial Virus) Monovalent Antigen in Healthy Participants 18 to 49 Years of Age

NCT07071558

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +5 more
Locations
  • Site # 0361003 Wollongong, New South Wales, Australia
  • Site # 0361006 Brisbane, Queensland, Australia
  • Site # 0361005 Morayfield, Queensland, Australia
  • Site # 0361004 Southport, Queensland, Australia
View Trial Details
Completed

Study of a Respiratory Syncytial Virus/Human Metapneumovirus/Parainfluenza Virus Type 3 Vaccine Candidate in Adults Aged 60 Years and Older

NCT06604767

Conditions
Infections, Metapneumovirus Infection, Mononegavirales Infections, +7 more
Locations
  • Investigational Site Number : 0360006 Blacktown, New South Wales, Australia
  • Investigational Site Number : 0360001 Botany, New South Wales, Australia
  • Investigational Site Number : 0360009 Brookvale, New South Wales, Australia
  • Investigational Site Number : 0360005 Kanwal, New South Wales, Australia
View Trial Details
Completed

A Follow-up Study to Describe the Safety of Study Participants Who Received RSVPreF3 Maternal Vaccination (Any Dose) or Controls From Previous RSV MAT Studies During Any Pregnancy Conceived Post Vaccination/Control

NCT05705440

Conditions
Infections, Mononegavirales Infections, Paramyxoviridae Infections, +4 more
Locations
  • GSK Investigational Site Mobile, Alabama, United States
  • GSK Investigational Site Phoenix, Arizona, United States
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Burbank, California, United States
View all 138 locations
View Trial Details

Related conditions